EUCTR2022-002891-35-FR进行中(未招募)1 期
REVErsing airway Remodelling with Tezepelumab (REVERT): a protocol for a double-blind randomized controlled trial for patients with asthma - REVERT
niversity Hospital of Montpellier0 个研究点目标入组 90 人开始时间: 2024年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Admitted to screening visit:
- •Minimum age: 18
- •Maximum age: 85
- •Able to perform an inspiratory and expiratory thoracic computed tomography (CT) scan, plus a nasal CT
- •Physician-diagnosed asthma according to GINA criteria
- •Disease with clinical impact: at least 1 severe or 2 moderate exacerbations† in the previous 12 months despite treatment according to the best standards of care
- •Maximal inhaled therapy comprising high dose ICS and at least a second controller according to GINA
- •Based on results of screening visit and run-in:
- •Post-bronchodilator forced expiratory volume in 1 second (FEV1) predicted values must be at 25-90%
- •Asthma Control Questionnaire 6 (ACQ6) > 1.5
- •Oral corticosteroid maintenance therapy (if used) is ?7.5 mg/day
- •In stable condition for the 4-week run-in period
- •On CT scan, the average percentage wall area index at the B1 and B8 bronchi (generation 3) is >65%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •CT abnormalities evocative of any respiratory condition other than asthma‡
- •Treatment regimen discordant with best practices
- •Pulmonary disease other than asthma‡ requiring treatment during the previous 12 months
- •A smoking history of >20 pack years
- •Biological therapy§ during the past 3 months
- •Absence of signed consent
- •Non-beneficiary of the French social security, single-payer health insurance system
- •Presence of any condition (physical, psychological or other) that might, in the investigator’s opinion, hinder study performance††
- •The patient is unavailable or unwilling to participate in future visits
- •Potential interference from other studies‡‡
- •Protected populations according to the French public health code§§
- •Male or female patients seeking to conceive a child
研究者
相似试验
已完成
3 期
REVErsing Airway Remodelling With TezepelumabAirway Remodelling, AsthmaticNCT05651841University Hospital, Montpellier90
进行中(未招募)
1 期
The Role of Benralizumab on airway Remodeling Assessed by HRCT in severe asthma (BREATH Study)SEVERE ASTHMAMedDRA version: 21.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2018-002498-23-ITAZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE” DI PALERMO20
已完成
不适用
Airway Remodeling During Mepolizumab TreatmentAsthmaNCT03797404Assistance Publique - Hôpitaux de Paris37
招募中
2 期
IMPD-Q-only application2024-516806-49-00AstraZeneca AB39
尚未招募
不适用
Tezepelumab Treatment in Korean Severe Asthma PatientsAsthmaNCT06438913Asan Medical Center100
